WEIFANG, China, Nov. 10 /Xinhua-PRNewswire-FirstCall/ -- Shengtai Pharmaceutical, Inc. (“Shengtai” or “the Company”), a leading manufacturer and distributor of high-quality, pharmaceutical grade glucose products in China, today announced that it will issue financial results for the three months ended September 30, 2008 after the close of the stock market on Thursday, November 13, 2008. Management will conduct a conference call on Friday, November 14, 2008 at 9:00 A.M. Eastern Standard Time to discuss these results. A question and answer session will follow management’s presentation.
Mr. Qingtai Liu (Chief Executive Officer), Ms. Yiru Melody Shi (CFO), and Ms. Michelle Wang (Investor Relations Manager) will be the primary speakers on the call.
A live webcast of the conference call will be available on the Investor Relations page of Shengtai Pharmaceutical’s web site at http://www.shengtaipharmaceutical.com . Please visit the Web site at least 15 minutes early to register for the webcast and download any necessary audio software.
To participate, please call the following numbers ten minutes before the call start time:
Phone Number: +1-877-407-8035 (North America)
Phone Number: +1-201-689-8035 (International)
A replay of the call will be available through Friday, November 21, 2008, at 11:59 P.M. Eastern Standard Time. For the replay, please call:
About Shengtai Pharmaceutical, Inc.
Shengtai Pharmaceutical, Inc. through its wholly owned subsidiary, Shengtai Holding, Inc. (SHI), a New Jersey corporation, and the Chinese operating company of Weifang Shengtai Pharmaceutical Co., Ltd., is a leading manufacturer and supplier of pharmaceutical grade glucose used for medical purposes. It also manufactures and supplies glucose and cornstarch products to the food, beverage and industrial production industries in China. For more information about Shengtai Pharmaceutical, Inc., please visit http://www.shengtaipharmaceutical.com .
Safe Harbor Statement
Certain statements in this press release and oral statements made by the Company constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. These statements include, without limitation, statements regarding our ability to prepare the Company for growth, the Company’s planned capacity expansion in 2008 and predictions and guidance relating to the Company’s future financial performance. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs, but they involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand especially in the pharmaceutical industry, pricing and demand trends for the Company’s products, changes to government regulations, risk associated with operation of the Company’s new facilities, risk associated with large-scale implementation of the Company’s business plan, the ability to attract new customers, ability to increase its product’s applications, cost of raw materials, downturns in the Chinese economy, and other information detailed from time to time in the Company’s filings and future filings with the United States Securities and Exchange Commission. Investors are urged to consider these factors carefully in evaluating the forward-looking statements herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company’s expectations.
CONTACT: Ms. Yiru Melody Shi, Chief Financial Officer Shengtai
Pharmaceutical, Inc., +1-949-468-7078, shengtaicfo@hotmail.com; or at
Grayling Global, Eddie Cheung, Investor Relations, +1-646-284-9414,
echeung@hfgcg.com, for SGTI
Web site: http://www.shengtaipharmaceutical.com/
